ABOUT BIOMARIN
Founded 25 years ago, 十大正规平台 is a global biotechnology company dedicated to transforming lives through genetic discovery.
Learn More about 十大正规平台 ⌃CAREERS AT BIOMARIN
Our focus on genetic disease gives us the opportunity to truly impact lives.
Learn More about careers with 十大正规平台 ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies
OUR PIPELINE
We maximize the impact of genetic innovation to develop transformative therapies.
We recently presented an update on our pipeline at our 2023 R&D Day. View the replay on our Investor
-
October 20, 2023U.S. Food and Drug Administration Approves 十大正规平台’s VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
-
October 17, 2023十大正规平台 to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
-
September 21, 2023十大正规平台 to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
-
September 15, 2023十大正规平台 Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
-
September 11, 2023十大正规平台 to Present Innovative Pipeline at R&D Day on September 12th in New York
-
September 6, 2023十大正规平台 to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
-
September 5, 2023十大正规平台 to Participate in Three Upcoming Investor Conferences
-
August 30, 2023十大正规平台 Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe